CompletedPhase 2

A Study of Disease Progression and Anti-HIV Treatments

United States210 participants

Plain-language summary

To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria Patients must have: * Prior participation on protocol ACTG 175. PER AMENDMENT 8/27/96: * Patients must be on study/on treatment at the time the protocol study treatment is extended.

Trial details

NCT IDNCT00001068

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)

Sponsor typeNIH

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More HIV Infections trials